anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Metabolic dysfunction-associated steatohepatitis-driven hepatocellular carcinoma (MASH-HCC) is a global clinical challenge for which there is a limited understanding of disease pathogenesis and a subsequent lack of therapeutic interventions. We previously identified that tumor necrosis factor-alpha (TNF-α) upregulated apoptosis antagonizing transcription factor (AATF) in MASH. Here, we investigated the effect of TNF-α converting enzyme (TACE) inhibition as a promising targeted therapy against AATF-mediated steatohepatitis to hepatocarcinogenesis. A preclinical murine model that recapitulates human MASH-HCC was used in the study. C57Bl/6 mice were fed with chow diet normal water (CD) or western diet sugar water (WD) along with a low dose of carbon tetrachloride (CCl4; 0.2 μL·g-1, weekly) for 24 weeks. TACE activity, TNF-α levels, and AATF expression were measured. The mice were treated with the TACE inhibitor Marimastat for 12 weeks, followed by analyses of liver injury, fibrosis, inflammation, and oncogenic signaling. In vitro experiments using stable clones of AATF control and AATF knockdown were also conducted. We found that AATF expression was upregulated in WD/CCl4 mice, which developed severe MASH at 12 weeks and advanced fibrosis with HCC at 24 weeks. WD/CCl4 mice showed increased TACE activity with reduced hepatic expression of sirtuin 1 (Sirt1) and tissue inhibitor of metalloproteinase 3 (Timp3). The involvement of the SIRT1/TIMP3/TACE axis was confirmed by the release of TNF-α, which upregulated AATF, a key molecular driver of MASH-HCC. Interestingly, TACE inhibition by Marimastat reduced liver injury, dyslipidemia, AATF expression, and oncogenic signaling, effectively preventing hepatocarcinogenesis. Furthermore, Marimastat inhibited the activation of JNK, ERK1/2, and AKT, which are key regulators of tumorigenesis in WD/CCl4 mice and in AATF control cells, but had no effect on AATF knockdown cells. This study shows that TACE inhibition prevents AATF-mediated inflammation, fibrosis, and oncogenesis in MASH-HCC, offering a potential target for therapeutic intervention.
Seventy-four consecutive patients with a long-standing history of symptomatic grade III or IV haemorrhoids were assigned randomly by means of a computer-generated list to conventional diathermy haemorrhoidectomy under spinal anaesthesia (group I); conventional diathermy haemorrhoidectomy with local anaesthesia combined with intravenous sedation (group II); Ligasure™ under spinal anaesthesia (group III) and Ligasure™ with local anaesthesia combined with intravenous sedation (group IV). Allocations were sealed in opaque numbered envelopes. All patients were operated on electively and by the same surgical team (two colorectal surgeons) and variables were collected after operation by an independent observer who was unaware of the operation performed.

The intraoperative time was measured. Intraoperative and early (within the first 48 h) postoperative complications associated with the surgical procedure and complications related to the anaesthetic technique (headache, vomiting, nausea, acute urinary retention, bleeding and hypotension) were recorded. A 100-mm visual analogue scale (VAS) was used to assess the intensity of pain, which was measured at 2, 6 and 24 hours postoperatively and during the first bowel movement. Seven days after surgery, patients were contacted by phone and the following data were recorded: VAS score at rest and during bowel movements, bleeding (categorised as 0 = none, 1 = occasional with defecation, 2 = with each defecation, 3 = with and without defecation) and pruritus (categorised as 0 = none, 1 = occasional, 2 = frequent) and tenesmus (categorised as 0 = none, 1 = occasional, 2 = frequent). These variables were collected at 4 and 12 months after operation by an independent observer who was unaware of the operation performed. Clinical evaluation at 1 year included relapse, continence according to the incontinence score system of Jorge and Wexner19, anal stenosis, presence of skin tags, patient's degree of satisfaction (where 0 corresponded to a unsatisfactory result and 10 an excellent result) and days of sick leave.
Low concentrations of circulating 25-hydroxy-vitamin D are observationally associated with an increased risk of subclinical atherosclerosis and cardiovascular disease. However, randomized controlled trials have not reported the beneficial effects of vitamin D supplementation on atherosclerotic cardiovascular disease (ASCVD) outcomes. Whether genetically predicted vitamin D status confers protection against the development of carotid artery plaque, a powerful predictor of subclinical atherosclerosis, remains unknown. We conducted a two-sample Mendelian randomization (MR) study to explore the association of genetically predicted vitamin D status and deficiency with the risk of developing carotid artery plaque. We leveraged three genome-wide association studies (GWAS) of vitamin D status and one GWAS of vitamin D deficiency. We used the inverse-variance weighted (IVW) approach as our main method, and MR-Egger, weighted-median, and radialMR as MR sensitivity analyses. We also conducted sensitivity analyses using biologically plausible genetic instruments located within genes encoding for vitamin D metabolism (GC, CYP2R1, DHCR7, CYP24A1). We did not find significant associations between genetically predicted vitamin D status (Odds ratio (OR) = 0.99, P = 0.91) and deficiency (OR = 1.00, P = 0.97) with the risk of carotid artery plaque. We additionally explored the potential causal effect of vitamin D status on coronary artery calcification (CAC) and carotid intima-media thickness (cIMT), two additional markers of subclinical atherosclerosis, and we did not find any significant association (βCAC = - 0.14, P = 0.23; βcIMT = 0.005, P = 0.19). These findings did not support the causal effects of vitamin D status and deficiency on the risk of developing subclinical atherosclerosis.
PURPOSE: Provided is an application of yellow soil as an additive in the preparation process of hair dyeing composition. Various minerals contained in yellow soil can alleviate toxicity, thereby giving glossiness as well as softness on hair. CONSTITUTION: To achieve the beforementioned purpose, firstly a predetermined amount of yellow soil is collected, screened, and disinfected to remove harmful factors. And then, the processed yellow soil is put in a container which is full of water. As time goes by, the mixture consisted of water and yellow soil is separated into two layers, i.e sediments precipitates at the bottom part and yellow soil supernatant is located in the upper part. The yellow soil supernatant is applied as an ingredient of additives for hair dyeing composition in the preparation process of sorts of hair dyes.
1,161,908. Rifamycins. CIBA Ltd. 22 Aug., 1966 [24 Aug., 1965], No. 37442/66. Heading C2A. The invention comprises a 3-substituted derivative of rifamycin S or of rifamycin SV, or of a 16, 17, 18, 19-tetrahydro or 16, 17, 18, 19, 28, 29-hexahydro derivative of rifamycin S or rifamycin SV, the substituent in position 3 being a free or aliphatically substituted amino group, namely, an amino group substituted by one or two monovalent hydrocarbon radicals of aliphatic character, which may be the same or different, or by a divalent hydrocarbon radical of aliphatic character, which hydrocarbons of aliphatic character may be interrupted in the carbon chain by one or more hetero atoms and may be unsubstituted or substituted, e.g. a heterocyclic grouping which is not aromatic; a salt thereof or a quaternary ammonium compound thereof. Examples thereof are 3-morpholino-rifamycin S, 3-pyrrolidino-rifamycin SV, 3-benzylamino rifamycin S, 3-piperidino-rifamycin SV, 3-cyclohexylaminorifamycin S and 3-methylamino-rifamycin SV. Rifamycin S has the following formula The compounds are prepared by reacting rifamycin S, or a 16, 17, 18, 19-tetrahydro or 16, 17, 18, 19, 28, 29 hexa-hydro derivative thereof, with ammonia or with a primary or secondary aliphatically substituted amine, and the 3-substituted derivative of rifamycin S and for the 3-substituted derivative of rifamycin SV so obtained is isolated, a hydroquinone obtained before or after the isolation being oxidized, if desired, to form a quinone and/or a quinone obtained before or after the isolation being reduced, if desired, to form a hydroquinone, and/or, if desired, a resulting compound is converted into a salt. Salts are formed with inorganic and organic acids (listed), and with metals. The picrates may be used in the purification of the bases. A pharmaceutical preparation having antibacterial activity comprises a rifamycin S or SV derivative as above, or a salt or quaternary ammonium compound thereof and a carrier. The compositions may be used orally, parenterally or topically. The rifamycin derivatives may also be added to animal fodders.
Embodiments of the present invention relate to a health support system and a recording medium. Target values of factors required for reducing the risk of diseases are efficiently determined. A health support system according to one embodiment includes a prediction unit, a target setting unit, a factor setting unit, and a target search unit. The predicting unit predicts a risk value of a disease based on physical examination data of a physical examiner. The target setting unit sets a reduction target for the risk value of the disease. The factor setting unit sets factors to be searched among the factors related to the disease and a search range of the factors. The target searching unit searches for a candidate for bringing the risk value of the disease close to the target value of each factor of the reduction target within the search range of each factor by using a predetermined search method.
Usual diabetic care for this study will include a diabetic visit with their primary care provider at the beginning and end of the 12 weeks. They will also be asked to continue their current level of physical activity and eating habits.
There is no specific antidote for overdose with INTELENCE®. Human experience of overdose with INTELENCE® is limited. The highest dose studied in healthy volunteers was 400 mg once daily. Treatment of overdose with INTELENCE® consists of general supportive measures including monitoring of vital signs and observation of the clinical status of the patient. If indicated, elimination of unabsorbed active substance is to be achieved by emesis or gastric lavage. Administration of activated charcoal may also be used to aid in removal of unabsorbed active substance. Because etravirine is highly protein bound, dialysis is unlikely to result in significant removal of the active substance.
PURPOSE:To obtain a solid type makeup cosmetic capable of blending a large amount of oily component while keeping powder in appearance and exhibiting high moisture-retaining property and moist feeling, etc., by blending powder for cosmetics and an oily component with fine powder of porous organic polymer having highly absorbing property. CONSTITUTION:This solid type makeup cosmetic is obtained by blending 1-75wt.% of powder for cosmetics with 3-50 pts.wt. of fine powder of highly oil-absorbing and porous organic polymer and 15-70wt.% of oily component and has simple usability and further has high moistening property and moistening feeling, etc. The fine powder of the highly oil-absorbing and porous organic polymer used in this cosmetic is preferably primary particles having 0.1-10mum size and forming higher order particles, and the higher order particles have oil absorbing property of 0.7-4.0 times based on the own weight. The solid type makeup cosmetic includes e.g. foundation or eye shadow. This cosmetic can blend a large amount of oily component and releases absorbed oil content by rubbing shear in coating when used and is rich in high moisture-retaining property and good moist feeling.
Participants will receive weekly food voucher (with a specified amount) for home delivery of omega-3 rich food (with a minimum of 4 grams of eicosapentaenoic acid (EPA) + docosahexaenoic acid (DHA) in the weekly food order) and personalized dietary coaching. Participant will also receive a single 1-hour one-on-one session (dietary motivational coaching) by a dietary coach to guide participants to consume at least 500 mg of EPA+DHA daily at the beginning of the study, followed by weekly 30-minute calls during the 12-week intervention study period.
PURPOSE: A composition and a health functional food containing cytochalasin b for preventing and treating cancer are provided to induce cancer cell apoptosis. CONSTITUTION: A composition for preventing and treating cancer contains cytochalasin b of chemical formula 1, or a pharmaceutically acceptable salt, an optical isomer, or a polymorph thereof as an active ingredient. The cancer includes uterine cervix cancer, colon cancer, anal cancer, esophageal cancer, pancreatic cancer, stomach cancer, kidney cancer, tongue cancer, oral cancer, skin cancer, uterine cancer, breast cancer, lymph gland cancer, thyroid cancer, prostate cancer, liver cancer, leukemia, skin cancer, colon carcinoma, brain tumor, bladder cancer, ovarian cancer, or gallbladder cancer. The composition induces cancer cell apoptosis. The composition suppresses DNA synthesis, generates early cell apoptosis, and causes oxidative stress. A health functional food for preventing and treating cancer contains the composition and a sitologically acceptable food additive. The health functional food is manufactured in the form of a powder, a granule, a tablet, a capsule, a pill, a suspension, an emulsion, and a syrup.
Participants will receive FENO 145 mg tablet orally once daily for 2 weeks in the pretreatment phase, then FIR 20 mg tablet once daily + CILO 30 mg tablet once daily + FENO 145 mg tablet orally once daily for 6 weeks in the treatment phase. Participants with compensated cirrhosis due to NASH will be accepted to participate in this cohort.
Fibromyalgia is a syndrome characterized mainly by chronic generalized pain that affects the physical fitness and the functional capacity of patients. There is growing evidence of the benefits of exercise to improve fibromyalgia symptoms, making these interventions part of the therapeutic arsenal. Objective: To evaluate the effectiveness of a functional exercise program in reducing pain, improving functional capacity, increasing muscle strength, improving flexibility, balance and quality of life of patients with fibromyalgia. METHODS: This was a randomized controlled trial with blind evaluator. 82 female patients with fibromyalgia were included, aged between 18 and 65 years, randomized into two groups, intervention and control. The intervention group performed functional physical training for 45 minutes twice a week for 14 weeks. The control group performed stretching exercises with the same duration and frequency. The evaluation instruments were: Visual Analog Scale for pain evaluation; Fibromyalgia Impact Questionnaire, to evaluate health-related quality of life; Time-up and go test for functional performance assessment; 1Repetitium Maximum, for evaluation of muscle strength; sit and reach test for the assessment of flexibility; Berg Balance Scale, to assess balance; and Short Form-36 to assess overall quality of life. In addition, the amount of analgesics used during the intervention period was evaluated.
29,604. Rossel, G. Dec. 23. Cosmetics.-A skin preparation for the nose comprises a mixture of gum, white of egg, sugar, and water. Preferably, 6 oz. gum are melted in ¢ pint of water, and the white of egg is beaten in 1¢ pints of water. The solutions are then mixed, and 4¢ lb. of sugar are added, the whole being heated, clarified, and cooled. Synthetic essence of lilies is preferred as a perfume for the preparation.
Capecitabine (825 mg/m\^2 twice a day, Monday-Friday during weeks 1, 2, 4, and 5) and Oxaliplatin (50 mg/m\^2, Days 1, 8, 22, 29) during the duration of radiation therapy only. Radiotherapy once daily on days 1-3, 6-10, 13-17, 20-24, 27-31, 34-38, and 41-42. Participants with T3-4 lesions undergo radiotherapy once daily on days 43 and 44. The final dose of radiation therapy determined by the T stage of the primary tumor. Radiotherapy = XRT.
PURPOSE:To obtain intraperitoneal adhesion inhibitor which contains xanthane gum as an active ingredient and can prevent intestines from adhering to each other or occluding to keep postoperative patients well. CONSTITUTION:The adhesion inhibitor includes xanthane gum, as an active ingredient, which is a microorganism-originating high-molecular-weight polysaccharide produced by Xanthomonas campestris. After celiotomy, the inhibitor is intraperitoneally poured to cover the operated site in an amount of 10 to 200ml. The adhesion inhibitor can contain medically active components, when needed, other than the gum. The intraperitoneal adhesion caused by tissue drying and bleeding on operation and by tissue damages accompanied surgery operation can be prevented. The xanthane gum is usually prepared into high viscous aqueous solution of 0.1 to 1.0W/V% concentration.
Chronic obstructive pulmonary disease (COPD) is commonly caused from smoking cigarettes that induce biological stress responses. Previously we found disorganized endoplasmic reticulum (ER) in fibroblasts from COPD with different responses to chemical stressors compared to healthy subjects. Here, we aimed to investigate differences in stress-related gene expressions within lung cells from COPD and healthy subjects. Bronchoalveolar lavage (BAL) cells were collected from seven COPD and 35 healthy subjects. Lung fibroblasts were derived from 19 COPD and 24 healthy subjects and exposed to cigarette smoke extract (CSE). Gene and protein expression and cell proliferation were investigated. Compared to healthy subjects, we found lower gene expression of CHOP in lung fibroblasts from COPD subjects. Exposure to CSE caused inhibition of lung fibroblast proliferation in both groups, though the changes in ER stress-related gene expressions (ATF6, IRE1, PERK, ATF4, CHOP, BCL2L1) and genes relating to proteasomal subunits mostly occurred in healthy lung fibroblasts. No differences were found in BAL cells. In this study, we have found that lung fibroblasts from COPD subjects have an atypical ER stress gene response to CSE, particularly in genes related to apoptosis. This difference in response to CSE may be a contributing factor to COPD progression.
1,146,800. Polypeptides. SOC. FARMACEUTICI ITALIA. 4 Aug., 1967 [9 Aug., 1966], No. 35884/67. Heading C2C. The novel decapeptide (I) Met - Asp - Phe - NH 2  in which the phenol group of the tyrosyl radical is free or blocked by a sulphuric residue and the hydroxy group of the threonyl radical is free or blocked by an aliphatic acyl radical containing 1-4 carbon atoms or its pharmaceutically acceptable salts is prepared by building up the peptide chain from aminoacids and/or peptide residues by methods known per se in the art. Intermediate peptides and derivatives are (1) prepared by reacting: (prepared by reacting carbo-t-butoxy-L-tyrosine and carbobenzoxy-hydrazine, followed by hydrolysis of CTB-Tyr-NHNHGBO) with CTBAsp(OBz)-OH and hydrolysing the product, CTB-Asp(OB 3 )-Tyr-NHNHCBO, to give reacting the latter with (where ONP is carbo-p-nitrophenyloxy) and hydrolysing the product, CTB-Glu(NH 2 )Asp (OBz)-Tyr-NHNHCBO, to give reacting the latter with to give and finally hydrogenating the latter to give the required product and (2) H-Thr(OAc)-Gly-Try-Met-Asp-Phe-NH 2  HCl prepared by reacting with to give reacting the latter with (where OCP is carbo-trichlorophenyloxy), which is prepared from via (whose DCHA is dicyclohexylamine) and and finally, hydrolysing the product to give the desired hexapeptide. Pharmaceutical compositions comprising a novel compound (I) in admixture with a suitable vehicle, are administered orally and parenterally. The compositions possess hypotensive activity and stimulate the motility of the gastroenteric duct and the secretions of the connected glands.
The invention relates to a Chinese traditional medicine for curing prostate disease, pertaining to the technical field of Chinese traditional medicine. The technical problem to be mainly solved is to cure the prostate disease. The key point of the technical proposal for solving the technical problem is that the invention is made by dodder and cassia twig and so on. The invention has the main functions and the technical effects of reinforcing kidney, transforming phlegm and softening hardness. The invention mainly cures hyperplasia of prostate (inflammation) and has the advantages of good curative effect, rapid effect, saving medicine, simple production technology, convenient taking, safe taking and low medicine price. Through clinic experiment, a plurality of patients get well.
Genexol-PM 100 mg/m2 intravenously for 1 hour on days 1, 8, and 15 of a 28-day cycle up to 8 cycles. Patients will receive study treatment until disease progression, unacceptable toxicity, or withdrawal of consent.
Psychotic depression is a severe and difficult-to-treat subtype of major depressive disorder for which higher rates of treatment-resistant depression were found. Studies have been performed aiming to predict treatment-resistant depression or treatment nonresponse. However, most of these studies excluded patients with psychotic depression. We created a genetic risk score (GRS) based on a large treatment-resistant depression genome-wide association study. We tested whether this GRS was associated with nonresponse, nonremission and the number of prior adequate antidepressant trials in patients with a psychotic depression. Using data from a randomized clinical trial with patients with a psychotic depression (n = 122), we created GRS deciles and calculated positive prediction values (PPV), negative predictive values (NPV) and odds ratios (OR). Nonresponse and nonremission were assessed after 7 weeks of treatment with venlafaxine, imipramine or venlafaxine plus quetiapine. The GRS was negatively correlated with treatment response (r = -0.32, p = 0.0023, n = 88) and remission (r = -0.31, p = 0.0037, n = 88), but was not correlated with the number of prior adequate antidepressant trials. For patients with a GRS in the top 10%, we observed a PPV of 100%, a NPV of 73.7% and an OR of 52.4 (p = 0.00072, n = 88) for nonresponse. For nonremission, a PPV of 100%, a NPV of 51.9% and an OR of 21.3 (p = 0.036, n = 88) was observed for patients with a GRS in the top 10%. Overall, an increased risk for nonresponse and nonremission was seen in patients with GRSs in the top 40%. Our results suggest that a treatment-resistant depression GRS is predictive of treatment nonresponse and nonremission in psychotic depression.
HemoHIM is a standardized medicinal herbal preparation consisting of extracts of Angelica gigas Nakai, Cnidium officinale Makino, and Paeonia lactiflora Pallas that possesses immune regulatory activities. This study aimed to research the potential antioxidant effects of HemoHIM and its capacity for reducing fatigue in aged mice subjected to forced exercise. After administering HemoHIM 125 (500 mg/kg orally) for 4 weeks in 8-month-old female C57BL/6 mice (4 groups of 10 mice), various parameters were evaluated. The analyses revealed that HemoHIM enhanced swimming time and grip strength. In addition, it significantly reduced serum lactate levels and increased liver glutathione peroxidase (GPx) levels after exercise challenge. The expression levels of antioxidant enzymes and factors, including nuclear factor erythroid 2-related factor-2 (Nrf-2), heme oxygenase 1, superoxide dismutase, GPx, and glutathione reductase, were significantly higher in liver and muscle tissues of mice treated with HemoHIM. These results indicate that HemoHIM might function as an anti-fatigue and antioxidant agent by modulating the Nrf-2 signaling pathway.